January 4, 2018
Allergan cuts more than 1000 jobs due to competition
Alergan will have to cut over 1000 jobs from commercial and other functions, the company said on Wednesday.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
January 3, 2018
FDA to improve generic drug review to enhance competition, promote access and lower drug prices
The FDA has announced more steps to encourage generic competition as part of its three-components Drug Competition Action Plan, by which…
January 3, 2018
Boehringer Ingelheim doubles funding to 250 M€ for its corporate venture fund
Boehringer Ingelheim today announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million.
January 3, 2018
Trends in OTC pharma packaging
While physically over-the-counter (OTC) medicine packaging may mirror the prescription drug market, with continued strong demand for plastic primary pharmaceutical…
January 3, 2018
Second breakthrough therapy mark for Novartis’s Kisqali
Novartis on Wednesday sadi that Kisqali has gotten US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based…
December 20, 2017
NIH study uncovers clues about why common cancer drug causes hearing loss
Scientists have found a new way to explain the hearing loss caused by cisplatin, a powerful drug used to treat…
December 20, 2017
FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss
The U.S. Food and Drug Administration has approved Spark Therapeutics’s Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult…
December 20, 2017
Portola Pharmaceuticals’s Bevyxxa available to patients in January 2018
U.S. Food and Drug Administration (FDA) has approved the Portola Pharmaceuticals’s Prior Approval Supplement (PAS) for Bevyxxa (betrixaban) ahead of…
December 20, 2017
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Boehringer Ingelheim today announced a collaborative agreement with Roche, focusing on the discovery and development of orally available novel Locked…
December 20, 2017
BioMarin doses first patient in global GENEr8-1 Phase 3 study
BioMarin Pharmaceutical has dosed the first patient in the global GENEr8-1 Phase 3 study with the 6e13 vg/kg dose for…